pre-miRNA Information | |
---|---|
pre-miRNA | mmu-mir-125a |
Genomic Coordinates | chr17: 17830812 - 17830879 |
Description | Mus musculus miR-125a stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . |
RNA Secondary Structure |
Mature miRNA Information | |
---|---|
Mature miRNA | mmu-miR-125a-5p |
Sequence | 6| UCCCUGAGACCCUUUAACCUGUGA |29 |
Evidence | Experimental |
Experiments | Cloned |
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | Ptpn7 | ||||||||||||||||||||
Synonyms | BPTP-4, C920001D21Rik, HEPTP, LC-PTP, LPTP | ||||||||||||||||||||
Description | protein tyrosine phosphatase, non-receptor type 7 | ||||||||||||||||||||
Transcript | NM_177081 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on Ptpn7 | |||||||||||||||||||||
3'UTR of Ptpn7 (miRNA target sites are highlighted) |
>Ptpn7|NM_177081|3'UTR 1 CCCTCCACCAGCTCATGGGTCTCTCAGGCCTGAGACAGTGGGTCTGGGGAAGTGGGCTGTGAGCTCTGGCATGGCTTCTG 81 CATCCGCACAGGAAAAGGATCCCTGGAATACTTTACAGTCTCAGGAAACTGCCCCAGCAAGCAACAGGAGCCAGGCCACG 161 GGTCTTCACCTCCAACCACGACTCTGCCTTCTTCAGTGGCCCCCAGTGGAACATGCGGGAGCGTCCTGTGGCTCTGAACT 241 TACAGATAGGAGCTGGTCCTTGCAATGGATTGAGAGAGCAGCTGGAGTGCTGGCTTATTTAGGTGCTTTCGGTGAGCTCC 321 CTTCCTTGTCCATGACACAAAGAGTCAGTCAAACAGAATGTTCCTGAAAGCCATTCCAGATGTAGCCCTGCTGATGCGGC 401 TGCAGAGATGGTGATTGCAAGATCCTCTTCCATTAAGGCCTTTCCCACACACAGGCCAGATGCAACAGCAGGGAAAATCC 481 TGGTCTGACCTTGGTCAAATCTTCTCTATCCTACATAGACTGCTCCTCCCCATACACCCGTGAGTGCTGGAGGACCGGCT 561 CAGAAGAGAATAAGGGCCTTGATTGGCCTGCCTCCATACATATCATAAAAGGAGATGCAGAGGTAACCAGCTCTAGCCGT 641 TGGGATCACTGTATGAGCCCAGAAGTGATGATGTACCTGTCATCCTAGCACTCAGGAGTAGAAGCAGGTGGGTTGCTGCG 721 AGTTTGAGGTCAGCTAGATCTACATTTTGAGTACCAGGCTAGCCAGGACAACATAGCAAGATTTTTTTTAAGGCAATCTT 801 GAGCTCTCTGCTCTCTGGAGGAGATGAGGGTTGCCTCTGCTTCTATGGCTTCCTTCCTGTCATCTGCTCCCAACCACTCT 881 CTGGGGGAAAACCCAGCACTCTCTGCTTTGCTTCTGTGACTTCAGAGCATCCTTTGGGTACCCATGAAGTATCAAAGAAA 961 GAGGAGAGAAGAGACAAAGAGCTATGTCTGCTTCAAGAAAACCTACCTGCCGTACCTCCCCTGGCTTGTATTTCTTTGCA 1041 GAGTGCTTATCTGGTTCCAGAAGCAGGCTGGGTGGTCACCACTCCAAGCAGCATGGGGCTAAGACCTTCAGCCCTCATCA 1121 TCATCACTTCACAGAATTTCCAGGGAACTCATGATCTATCTCAGGGATGAACTATGAATCCCAGAAAGCCAGACAAACCC 1201 TGAGTCTCCCTTGACCCGGATTGGGCTGCCTGTGGGGGGGAAGGCAGAATACTATTCCTACTGTCTGGTCCTCAGCTCCT 1281 GGATGTGCTAAGTGACACAAGTCCTCCATGAAAACCCCAAGGAGTTGGAGGAGTGACTGCCTCCTTGCTTCCTGGCATCT 1361 CTCTGGAGAACTCGAAGTGCTTCTGGACATAGTGTCGAAAGCCTGTGAGCCGCACTTGGACAGGGAAGACAGGAGAATCG 1441 GGAGTTCCAGACCAGCCTTGGCGATGTGAGACCCAATCTCAAAAGCAAGCAAACAAAAAGAAACTAAGCAGCGGGGCATG 1521 GTGGTGCATACCTTTAATTCCAGCACTCGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCAAGGCCAGCCTGGTCTACAAA 1601 GTGAGTTCCAGGACAGCCAGGGCTATACAGAGAAACCCTGCCTCGAAAGAAAAAAAAAAGAAAGAAAGAAAGAAAGAAAG 1681 AAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAAGAAACGAAACTAAACAAACAAACAAACAAACAAAAATAATGTGA 1761 GGCTACAACTGAGGTTAACATTTTTAATGCTCGACCTGAGCTGAGTAGGTGCTCTGCTTCTTTAGTCTTGGGGTGGTGGC 1841 TTGCACTTCCACTTTTTTTTTAAGTCCCCTGAAAGGTCTGCACTGCTGCCCAGGATAGGCTTCTAAAGTACAGGATGCTA 1921 CATGAGCTCAGAGACTGTATAGAAGGGTGCAAGGGAGCAATTGTACAGCCCTATGGGCTCCCTCCCTATACAGTCACCCC 2001 AACCCTGTTCTAGAGGGCACAGGCTCTGGAAAAGCATAATAAATAAATAAATAACCTCTTGGATGC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | mouse |
Disease | 320139.0 |
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
"miR-125a significantly down-regulated the 3芒鈧虏UTR reporters of multiple protein phosphatases
... - Guo S; Bai H; Megyola CM; Halene S; Krause et al., 2012, Proceedings of the National Academy of Sciences of the United States of America. |
Article |
- Guo S; Bai H; Megyola CM; Halene S; Krause et al. - Proceedings of the National Academy of Sciences of the United States of America, 2012
Deregulation of microRNA (miRNA) expression can lead to cancer initiation and progression. However, limited information exists on the function of miRNAs in cancer maintenance. We examined these issues in the case of myeloproliferative diseases and neoplasms (MPN), a collection of hematopoietic neoplasms regarded as preleukemic, thereby representing early neoplastic states. We report here that microRNA-125a (miR-125a)-induced MPN display a complex manner of oncogene dependence. Following a gain-of-function genomics screen, we overexpressed candidate miR-125a in vivo, which led to phenotypes consistent with an atypical MPN characterized by leukocytosis, monocytosis, splenomegaly, and progressive anemia. The diseased MPN state could be recapitulated in a doxycycline-inducible mouse model. Upon doxycycline withdrawal, the primary MPN phenotypes rapidly resolved after the discontinuation of miR-125a overexpression. However, reinduction of miR-125a led to complex phenotypes, with some animals rapidly developing lethal anemia with extensive damages in the spleen. Forced expression of miR-125a resulted in elevated cellular tyrosine phosphorylation and hypersensitivity toward hematopoietic cytokines. Furthermore, we demonstrate that miR-125a targets multiple protein phosphatases. Our data demonstrate that miR-125a-induced MPN is addicted to its sustained overexpression, and highlight the complex nature of oncogenic miRNA dependence in an early neoplastic state.
LinkOut: [PMID: 23012470]
|
28 mmu-miR-125a-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT001716 | Lin28a | lin-28 homolog A (C. elegans) | 1 | 1 | ||||||||
MIRT005597 | Trim71 | tripartite motif-containing 71 | 4 | 3 | ||||||||
MIRT006310 | Cbx7 | chromobox 7 | 2 | 1 | ||||||||
MIRT006967 | 4632428N05Rik | V-set immunoregulatory receptor | 2 | 1 | ||||||||
MIRT054177 | Ptpn18 | protein tyrosine phosphatase, non-receptor type 18 | 2 | 1 | ||||||||
MIRT054178 | Ptpn7 | protein tyrosine phosphatase, non-receptor type 7 | 2 | 1 | ||||||||
MIRT054179 | Ppp1ca | protein phosphatase 1, catalytic subunit, alpha isoform | 2 | 1 | ||||||||
MIRT054180 | Ppp2ca | protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform | 2 | 1 | ||||||||
MIRT054570 | Traf6 | TNF receptor-associated factor 6 | 3 | 1 | ||||||||
MIRT580227 | Tspan12 | tetraspanin 12 | 2 | 2 | ||||||||
MIRT582368 | Mtf1 | metal response element binding transcription factor 1 | 2 | 2 | ||||||||
MIRT582450 | Mgat4a | mannoside acetylglucosaminyltransferase 4, isoenzyme A | 2 | 2 | ||||||||
MIRT584884 | Antxr2 | anthrax toxin receptor 2 | 2 | 2 | ||||||||
MIRT587193 | Foxk1 | forkhead box K1 | 2 | 2 | ||||||||
MIRT588848 | Snrnp40 | small nuclear ribonucleoprotein 40 (U5) | 2 | 2 | ||||||||
MIRT591275 | Lars2 | leucyl-tRNA synthetase, mitochondrial | 2 | 4 | ||||||||
MIRT592914 | Madd | MAP-kinase activating death domain | 2 | 2 | ||||||||
MIRT594893 | Il1rn | interleukin 1 receptor antagonist | 2 | 4 | ||||||||
MIRT596427 | Hif1an | hypoxia-inducible factor 1, alpha subunit inhibitor | 3 | 3 | ||||||||
MIRT599142 | Dqx1 | DEAQ RNA-dependent ATPase | 2 | 2 | ||||||||
MIRT599717 | Aph1c | aph1 homolog C, gamma secretase subunit | 2 | 2 | ||||||||
MIRT600832 | Gm14137 | predicted gene 14137 | 2 | 2 | ||||||||
MIRT604902 | Jmy | junction-mediating and regulatory protein | 2 | 2 | ||||||||
MIRT605441 | Stat1 | signal transducer and activator of transcription 1 | 2 | 2 | ||||||||
MIRT606092 | Wdr25 | WD repeat domain 25 | 2 | 2 | ||||||||
MIRT732537 | Tnfrsf1b | tumor necrosis factor receptor superfamily, member 1b | 4 | 0 | ||||||||
MIRT734700 | VDR | vitamin D receptor | 2 | 0 | ||||||||
MIRT734824 | Sox11 | SRY (sex determining region Y)-box 11 | 2 | 0 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|